| Revista: | Revista de investigación clínica |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000454146 |
| ISSN: | 0034-8376 |
| Autores: | Solórzano Santos, Fortino1 Quezada Herrera, Anai2 Fuentes Pacheco, Yazmín3 Rodríguez Coello, Genoveva4 Aguirre Morales, Carlos E5 Izelo Flores, Dassaev6 Muñoz Hernández, Onofre7 Miranda Novales, María G8 |
| Instituciones: | 1Hospital Infantil de México "Federico Gómez", Unidad de Investigación en Medicina Basada en Evidencia, Ciudad de México. México 2Hospital del Niño y del Adolescente Morelense, Cuernavaca, Morelos. México 3Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Ciudad de México. México 4Hospital para el Niño Poblano, Puebla. México 5Centro Médico ABC, Ciudad de México. México 6Instituto Mexicano del Seguro Social, Hospital General de Zona 20, Puebla. México 7Hospital Infantil de México "Federico Gómez", Ciudad de México. México 8Instituto Mexicano del Seguro Social, Coordinación de Investigación en Salud, Ciudad de México. México |
| Año: | 2019 |
| Periodo: | Jul-Ago |
| Volumen: | 71 |
| Número: | 4 |
| Paginación: | 283-290 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | Background Febrile neutropenia (FN) is a common complication in children who receive chemotherapy for cancer. Objective The objective of this study was to evaluate the clinical efficacy of the continuous versus intermittent infusion of piperacillin/tazobactam (TZP) in febrile neutropenic pediatric patients. Methods This is a non-blinded randomized controlled clinical trial. Eligible group consisted of hemato-oncological patients with FN who were candidates to receive TZP. Patients were randomized to one of two groups: Group 1 received antibiotic treatment through intravenous intermittent infusion of TZP 300 mg/kg/day based on piperacillin, divided into four doses, not exceeding 16 g/day; Group 2 received an initial TZP loading dose of 75 mg/kg infusion over 30 min, and then a continuous infusion of TZP 300 mg/kg/day through central line with pump over 24 h. Results There were 176 episodes that could be assessed, 100 in Group 1 and 76 in Group 2. There was no statistically significant difference in treatment failure in the experimental group (continuous infusion) compared with the intermittent group, 21% versus 13% (p = 0.15). The increase in the absolute risk reduction was 0.08% (95% confidence interval 0.12-0.30), and the number needed to treat was 12.4. One patient in each group died. Conclusions There were no differences in fever resolution, clinical cure rate, or mortality when comparing the continuous with the intermittent TZP infusion |
| Disciplinas: | Medicina |
| Palabras clave: | Oncología, Farmacología, Pediatría, Quimioterapia, Efectos secundarios, Neutropenia febril, Infusión, Piperacilina, Tazobactam |
| Keyword: | Oncology, Pharmacology, Pediatrics, Chemotherapy, Secondary effects, Febrile neutropenia, Infusion, Piperacillin, Tazobactam |
| Texto completo: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
